Celularity Statistics
Total Valuation
Celularity has a market cap or net worth of $27.56 million. The enterprise value is $96.81 million.
| Market Cap | 27.56M |
| Enterprise Value | 96.81M |
Important Dates
The last earnings date was Tuesday, October 20, 2026, after market close.
| Earnings Date | Oct 20, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
Celularity has 32.45 million shares outstanding. The number of shares has increased by 23.65% in one year.
| Current Share Class | 32.45M |
| Shares Outstanding | 32.45M |
| Shares Change (YoY) | +23.65% |
| Shares Change (QoQ) | -3.15% |
| Owned by Insiders (%) | 10.92% |
| Owned by Institutions (%) | 11.70% |
| Float | 22.37M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 1.48 |
| Forward PS | n/a |
| PB Ratio | n/a |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 5.19 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 0.11
| Current Ratio | 0.11 |
| Quick Ratio | 0.09 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -16.33 |
Financial Efficiency
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | -27.38% |
| Return on Invested Capital (ROIC) | -140.98% |
| Return on Capital Employed (ROCE) | -123.58% |
| Weighted Average Cost of Capital (WACC) | 4.76% |
| Revenue Per Employee | $162,313 |
| Profits Per Employee | -$402,061 |
| Employee Count | 115 |
| Asset Turnover | 0.17 |
| Inventory Turnover | 5.88 |
Taxes
In the past 12 months, Celularity has paid $3,000 in taxes.
| Income Tax | 3,000 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -57.54% in the last 52 weeks. The beta is 0.78, so Celularity's price volatility has been lower than the market average.
| Beta (5Y) | 0.78 |
| 52-Week Price Change | -57.54% |
| 50-Day Moving Average | 1.32 |
| 200-Day Moving Average | 1.09 |
| Relative Strength Index (RSI) | 37.32 |
| Average Volume (20 Days) | 179,617 |
Short Selling Information
The latest short interest is 441,798, so 1.36% of the outstanding shares have been sold short.
| Short Interest | 441,798 |
| Short Previous Month | 391,276 |
| Short % of Shares Out | 1.36% |
| Short % of Float | 1.97% |
| Short Ratio (days to cover) | 3.17 |
Income Statement
In the last 12 months, Celularity had revenue of $18.67 million and -$46.24 million in losses. Loss per share was -$1.63.
| Revenue | 18.67M |
| Gross Profit | 3.59M |
| Operating Income | -47.42M |
| Pretax Income | -45.86M |
| Net Income | -46.24M |
| EBITDA | -42.57M |
| EBIT | -47.42M |
| Loss Per Share | -$1.63 |
Balance Sheet
The company has $586,000 in cash and $69.83 million in debt, with a net cash position of -$69.25 million or -$2.13 per share.
| Cash & Cash Equivalents | 586,000 |
| Total Debt | 69.83M |
| Net Cash | -69.25M |
| Net Cash Per Share | -$2.13 |
| Equity (Book Value) | -33.59M |
| Book Value Per Share | -1.21 |
| Working Capital | -51.35M |
Cash Flow
| Operating Cash Flow | -8.92M |
| Capital Expenditures | n/a |
| Depreciation & Amortization | 4.85M |
| Net Borrowing | 5.15M |
| Free Cash Flow | -8.92M |
| FCF Per Share | -$0.27 |
Margins
Gross margin is 19.23%, with operating and profit margins of -254.03% and -245.68%.
| Gross Margin | 19.23% |
| Operating Margin | -254.03% |
| Pretax Margin | -245.66% |
| Profit Margin | -245.68% |
| EBITDA Margin | -228.03% |
| EBIT Margin | -254.03% |
| FCF Margin | n/a |
Dividends & Yields
Celularity does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -23.65% |
| Shareholder Yield | -23.65% |
| Earnings Yield | -192.48% |
| FCF Yield | -32.38% |
Analyst Forecast
| Price Target | n/a |
| Price Target Difference | n/a |
| Analyst Consensus | n/a |
| Analyst Count | n/a |
| Revenue Growth Forecast (3Y) | 157.40% |
| EPS Growth Forecast (3Y) | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
The last stock split was on February 29, 2024. It was a reverse split with a ratio of 1:10.
| Last Split Date | Feb 29, 2024 |
| Split Type | Reverse |
| Split Ratio | 1:10 |
Scores
Celularity has an Altman Z-Score of -16.27 and a Piotroski F-Score of 2. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -16.27 |
| Piotroski F-Score | 2 |